alpha-D-Glucose
|
Basic information |
| Metabolite name | alpha-D-Glucose |
 | HMDB0003345 |
 |
C00267 |
 |
79025 |
| Synonyms | alpha-D-Glucopyranoside; |
| No. of studies | 33 |
|
Basic information |
| Metabolite name | alpha-D-Glucose |
| HMDB0003345 |
|
C00267 |
|
79025 |
| Synonyms | alpha-D-Glucopyranoside; |
| No. of studies | 33 |
|
Relationship between alpha-D-Glucose and depression (count: 33) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type2 | CUMS + QZ group vs. CUMS group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Down |
| Study M051 | Type3 | fluoxetine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M056 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M066 | Type1 | CUMS vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M085 | Type3 | ketamine group vs. control group at 24 h after treatment | Serum | Cynomolgus monkey | Down |
| Study M094 | Type1 | PSD group vs. stroke and control group | Urine | Human | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M108 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, female offspring | Faece | ICR mouse | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M118 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M146 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + middle dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + low dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Up |
| Study M207 | Type1 | depressed group vs. control group | Hippocampus | Kunming mouse | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Down |
| Study M512 | Type1 | CUMS group vs. control group | Urine | Goto-Kakizaki rat | Down |
| Study M512 | Type1 | CUMS group vs. control group | Plasma | Goto-Kakizaki rat | Down |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + high dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + low dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + median dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + augmentation treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Urine | Human | Unknown |
| Study M584 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + low dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + low dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of negative control treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M591 | Type1 | LPS group vs. control group | Plasma | CD-1 mouse | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Up |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Down |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Down |
| Study M739 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M739 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M740 | Type1 | CUMS group vs. control group | Gastrocnemius muscle | Sprague-Dawley rat | Up |
| Study M740 | Type2 | CUMS + endurance exercise group vs. CUMS group | Gastrocnemius muscle | Sprague-Dawley rat | Down |
| Study M809 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Up |
| Study M809 | Type2 | CUMS + Milletia speciosa Champ group vs. CUMS group | Serum | Kunming mouse | Down |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + low dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M935 | Type2 | chronic social isolation + tianeptine group vs. chronic social isolation group | Hippocampus | Wistar rat | Up |